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Graft Biology: Marrow Versus Peripheral
Blood Versus Cord Blood
Richard Champlin
Bone marrow, mobilized peripheral blood, and
cord blood are all sources of hematopoietic and im-
mune cells. Each source has advantages and disadvan-
tages for hematopoietic transplantation. This session
reviews current data and explores the role of each of
these stem cell sources.
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Peripheral blood stem cells (PBSCs) are increas-
ingly being used for related and unrelated donor he-
matopoietic stem cell transplantation. Collection of
PBSCs rather than bone marrow (BM) offers several
advantages to the donor, including avoidance of anes-
thesia, hospitalization, and potential exposure to
blood products, although controlled comparisons of
PBSC and BM donation do not indicate substantial
differences in serious adverse effects. There are nu-
merous reports, including randomized trials, compar-
ing recipient outcomes after PBSC and BM transplan-
tation from HLA-matched sibling donors, but the
median follow-up of surviving patients is less than 3
years. Most data support a higher risk of chronic
graft-versus-host disease with PBSCs than with BM
grafts, and some support a survival advantage with
PBSCs in recipients of transplantation for advanced
leukemia. A convincing survival advantage for those
with early leukemia has not yet been documented.
Despite increasing numbers of unrelated donor PBSC
transplantations, there are few reports describing out-
comes in these groups of patients and none supporting
a survival advantage for acute or chronic leukemia
among PBSC recipients.
The Center for International Blood and Marrow
Transplant Research (CIBMTR), in collaboration
with the European Group for Blood and Marrow
Transplantation (EBMT), examined long-term out-
comes after PBSC and BM transplantation in patients
with acute and chronic leukemia. The ﬁrst report with
a median follow-up of 1 year showed higher chronic
GVHD, lower transplantation-related mortality, and
greater leukemia-free survival in patients with ad-
vanced leukemia at the time of transplantation [1].
Long-term follow-up data were obtained for 413 of
491 patients who were alive at the time of the initial
report: 141 PBSC recipients and 272 BM recipients,
with a median follow-up of more than 6 years [2].
Consistent with the initial report, chronic GVHD was
Figure 1. Probability of leukemia-free survival in patients with
chronic leukemia after BM and PBSC transplants adjusted for
disease status at transplantation (N  number of evaluable patients;
%  the 6-year rate of leukemia-free survival).
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